Free Trial
NASDAQ:SPRB

Spruce Biosciences (SPRB) Stock Price, News & Analysis

Spruce Biosciences logo
$0.06 0.00 (-4.13%)
As of 03:08 PM Eastern

About Spruce Biosciences Stock (NASDAQ:SPRB)

Key Stats

Today's Range
$0.06
$0.06
50-Day Range
$0.06
$0.34
52-Week Range
$0.06
$0.76
Volume
24,865 shs
Average Volume
729,616 shs
Market Capitalization
$2.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.17
Consensus Rating
Hold

Company Overview

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Spruce Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

SPRB MarketRank™: 

Spruce Biosciences scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Spruce Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Spruce Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Spruce Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Spruce Biosciences are expected to grow in the coming year, from ($1.00) to ($0.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spruce Biosciences is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spruce Biosciences is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Spruce Biosciences has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.36% of the float of Spruce Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Spruce Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spruce Biosciences has recently increased by 275.29%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Spruce Biosciences does not currently pay a dividend.

  • Dividend Growth

    Spruce Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.36% of the float of Spruce Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Spruce Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spruce Biosciences has recently increased by 275.29%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    2 people have searched for SPRB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Spruce Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.10% of the stock of Spruce Biosciences is held by insiders.

  • Percentage Held by Institutions

    91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Spruce Biosciences' insider trading history.
Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SPRB Stock News Headlines

Spruce Biosciences Inc Ordinary Shares
Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Spruce Biosciences (SPRB) Receives a Hold from RBC Capital
See More Headlines

SPRB Stock Analysis - Frequently Asked Questions

Spruce Biosciences' stock was trading at $0.42 at the beginning of 2025. Since then, SPRB shares have decreased by 85.6% and is now trading at $0.0604.
View the best growth stocks for 2025 here
.

Spruce Biosciences, Inc. (NASDAQ:SPRB) announced its quarterly earnings results on Tuesday, April, 15th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.37. The company earned $0.55 million during the quarter, compared to analysts' expectations of $0.50 million. Spruce Biosciences had a negative net margin of 555.23% and a negative trailing twelve-month return on equity of 62.10%.

Spruce Biosciences (SPRB) raised $75 million in an IPO on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets served as the underwriters for the IPO.

Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spruce Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE), Meta Platforms (META) and Disc Medicine (IRON).

Company Calendar

Last Earnings
4/15/2025
Today
5/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SPRB
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.17
High Stock Price Target
$3.00
Low Stock Price Target
$0.50
Potential Upside/Downside
+3,487.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-47,920,000.00
Net Margins
-555.23%
Pretax Margin
-555.23%

Debt

Sales & Book Value

Annual Sales
$4.91 million
Price / Cash Flow
N/A
Book Value
$1.88 per share
Price / Book
0.03

Miscellaneous

Free Float
37,544,000
Market Cap
$2.55 million
Optionable
Optionable
Beta
2.49
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:SPRB) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners